Magair-S

Magnesium oxide, the active ingredient in Magair‑S, is a mineral supplement presented as an oral dosage form for oral use. It helps correct low magnesium levels, can neutralize excess stomach acid, and may be used as an osmotic laxative in appropriate patients. The compound is widely used in clinical practice across the EU for nutritional support and gastrointestinal relief.

GNH USA supplies Magair‑S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European quality standards and provides regulatory documentation for global distribution.

Magair‑S (magnesium oxide) is used to address magnesium deficiency, neutralize gastric acidity, and promote bowel movements as an osmotic laxative. - Magnesium deficiency: restores normal magnesium levels and supports muscle and nerve function. - Acid indigestion: neutralizes excess gastric acid to relieve heartburn and dyspepsia. - Occasional constipation: draws water into the intestinal lumen to facilitate stool passage.

Magair‑S may be associated with a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Diarrhea: loose stools due to osmotic activity. - Abdominal cramping: mild stomach discomfort. - Nausea: feeling of sickness. Serious or Rare Side Effects: - Hypermagnesemia: high serum magnesium that can cause muscle weakness, low blood pressure, or cardiac rhythm changes. - Severe allergic reaction: rash, swelling, or breathing difficulty. - Electrolyte imbalance: abnormal calcium or potassium levels.

When prescribing or dispensing Magair‑S, several precautions should be observed to minimize risk. - Renal function assessment: avoid or adjust use in patients with severe renal impairment. - Serum magnesium monitoring: check levels during prolonged therapy. - Concomitant cardiac conditions: use cautiously in patients with heart block or arrhythmias. - Drug interaction awareness: review concurrent use of antibiotics or muscle relaxants that may affect absorption. - Pregnancy and lactation: consider risk‑benefit; use only if clearly needed. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Magair‑S can affect the absorption or activity of several medicines; interactions are grouped by clinical significance. Major Interactions (Avoid): - Tetracycline antibiotics: reduced absorption; separate administration by at least 2 hours. - Fluoroquinolone antibiotics: decreased effectiveness; separate dosing. - Bisphosphonates: impaired uptake; administer at different times. Moderate Interactions (Monitor Closely): - Warfarin: possible increase in anticoagulant effect; monitor INR. - Digoxin: potential increase in serum levels; observe for toxicity. - Iron supplements: decreased magnesium absorption; stagger dosing.